Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Lurbinectedin (Primary) ; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 28 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 May 2020.
- 28 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 May 2019.
- 20 May 2016 Status changed from not yet recruiting to recruiting, according to a PharmaMar media release.